**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 57925

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma**

Atwa SM *et al.* Pivotal role of XIST in regulating immune checkpoint PD-L1 through a shared pathway between miR-194-5p and miR-155-5p in HCC

Sara M Atwa, Heba Handoussa, Karim M Hosny, Margarete Odenthal, Hend M El Tayebi

**Sara M Atwa, Heba Handoussa,** Pharmaceutical Biology Department, German University in Cairo, Cairo 11865, Egypt

**Karim M Hosny,** Department of General Surgery, Faculty of Medicine, Cairo University, Cairo 11562, Egypt

**Margarete Odenthal,** Institute for Pathology, University Hospital Cologne, Cologne 50924, Germany

**Hend M El Tayebi,** Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt

**Author contributions:** El-Tayebi HM and Odenthal M designed and coordinated the study; El-Tayebi HM supported data interpretation and analysis; Handoussa H designed and supervised the natural product study; Atwa SM performed the experiments, acquired and analyzed the data and wrote the manuscript; Hosny KA provided tissue samples and clinical data; all authors approved the final version of the article to be published.

**Corresponding author: Hend M El Tayebi, PhD, Assistant Professor, Lecturer, Pharmacist, Senior Postdoctoral Fellow,** Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, New Cairo City - Main Entrance Al Tagamoa Al Khames, Cairo 11835, Egypt. hend.saber@guc.edu.eg

**Received:** June 30, 2020

**Revised:** September 30, 2020

**Accepted:** October 29, 2020

**Published online:** December 27, 2020

**Abstract**

BACKGROUND

Anti-programmed death therapy has thrust immunotherapy into the spotlight. However, such therapy has a modest response in hepatocellular carcinoma (HCC). Epigenetic immunomodulation is a suggestive combinatorial therapy with immune checkpoint blockade. Non-coding ribonucleic acid (ncRNA) driven regulation is a major mechanism of epigenetic modulation. Given the wide range of ncRNAs that co-opt in programmed cell-death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) regulation, and based on the literature, we hypothesized that miR-155-5p, miR-194-5p and long non-coding RNAs (lncRNAs) X-inactive specific transcript (XIST) and MALAT-1 are involved in a regulatory upstream pathway for PD-1/PD-L1. Recently, nutraceutical therapeutics in cancers have received increasing attention. Thus, it is interesting to study the impact of oleuropein on the respective study key players.

AIM

To explore potential upstream regulatory ncRNAs for the immune checkpoint PD-1/PD-L1.

METHODS

Bioinformatics tools including microrna.org and lnCeDB software were adopted to detect targeting of miR-155-5p, miR-194-5p and lncRNAs XIST and MALAT-1 to PD-L1 mRNA, respectively. In addition, Diana tool was used to predict targeting of both aforementioned miRNAs to lncRNAs XIST and MALAT-1. HCC and normal tissue samples were collected for scanning of PD-L1, XIST and MALAT-1 expression. To study the interaction among miR-155-5p, miR-194-5p, lncRNAs XIST and MALAT-1, as well as PD-L1 mRNA, a series of transfections of the Huh-7 cell line was carried out.

RESULTS

Bioinformatics software predicted that miR-155-5p and miR-194-5p can target PD-L1, MALAT-1 and XIST. MALAT-1 and XIST were predicted to target PD-L1 mRNA. PD-L1 and XIST were significantly upregulated in 23 HCC biopsies compared to healthy controls; however, MALAT-1 was barely detected. MiR-194 induced expression elevated the expression of PD-L1, XIST and MALAT-1. However, overexpression of miR-155-5p induced the upregulation of PD-L1 and XIST, while it had a negative impact on MALAT-1 expression. Knockdown of XIST did have an impact on PD-L1 expression; however, following knockdown of the negative regulator of X-inactive specific transcript (TSIX), PD-L1 expression was elevated, and abolished MALAT-1 activity. Upon co-transfection of miR-194-5p with siMALAT-1, PD-L1 expression was elevated. Co-transfection of miR-194-5p with siXIST did not have an impact on PD-L1 expression. Upon co-transfection of miR-194 with siTSIX, PD-L1 expression was upregulated. Interestingly, the same PD-L1 expression pattern was observed following miR-155-5p co-transfections. Oleuropein treatment of Huh-7 cells reduced the expression profile of PD-L1, XIST, and miR-155-5p, upregulated the expression of miR-194-5p and had no significant impact on the MALAT-1 expression profile.

CONCLUSION

This study reported a novel finding revealing that opposing acting miRNAs in HCC, have the same impact on PD-1/PD-L1 immune checkpoint by sharing a common signaling pathway.

**Key Words:** Hepatocellular carcinoma; X-inactive specific transcript; MiR-155-5p; MiR-194-5p; Programmed cell-death protein 1/Programmed death ligand 1; Immune checkpoint

**Citation:** Atwa SM, Handoussa H, Hosny KM, Odenthal M, El Tayebi HM. Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. *World J Hepatol* 2020; 12(12): 1211-1227

**URL:** https://www.wjgnet.com/1948-5182/full/v12/i12/1211.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v12.i12.1211

**Core Tip:** Due to the immune rich milieu of hepatocellular carcinoma (HCC), it is a good candidate for immune-based therapies. In this study, our aim was to identify potential upstream epigenetic regulators of immune checkpoint programmed cell-death protein 1/programmed death ligand 1 in HCC which could be regarded as therapeutic targets. The findings of this study revealed the re-questioning of the role of certain non-coding ribonucleic acids in HCC. Here we deduced a novel shared upstream regulatory signaling pathway for programmed cell-death protein 1/programmed death ligand 1 immune checkpoint between paradoxically acting tumor suppressor miR-194-5p and onco-miR-155-5p, in HCC through X-inactive specific transcript expression modulation.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) constitutes a global burden and is one of the leading causes of cancer mortality[[1](#_ENREF_1" \o "Yang, 2019 #2)]. A myriad of therapeutic modalities is available for HCC including tumor resection or ablation, transarterial chemoembolization, liver transplantation and treatment with tyrosine kinase inhibitors[[2](#_ENREF_2" \o "Llovet, 2015 #287)]. Nevertheless, HCC is a highly therapy resistant disease and is frequently diagnosed at an advanced stage; thus, the identification of a novel therapeutic modality is essential[[3](#_ENREF_3" \o "Llovet, 2018 #289)].

Recently, tumour immunotherapy has been thrust into the spotlight to inhibit tumour progression, relapse and metastasis. Immunotherapeutic techniques comprise both activation of tumour specific immune responses as well as enhancement of cellular or humoral immunity thus causing disruption of immune tolerance[[4](#_ENREF_4" \o "Xie, 2018 #291)]. HCC immunotherapy has greatly changed due to extensive ongoing immunological studies which have incorporated immunotherapy into the HCC treatment armamentarium[[5](#_ENREF_5" \o "Ji, 2018 #202)]. The rationale behind such a revolutionary therapeutic technique is the fact that HCC develops in an inflammatory milieu brimming with tumour infiltrating lymphocytes boosting HCC immunogenicity[[6](#_ENREF_6" \o "Flecken, 2014 #290)].

Immune checkpoint inhibitors have been featured as a sensational paradigm shift in cancer immunotherapy[[7](#_ENREF_7" \o "Mellman, 2011 #294)]. Physiologically, immune checkpoints are co-inhibitory molecules that act as “brakes” in the immune system to avoid an exaggerated response and restore its activity to a normal level[[8](#_ENREF_8" \o "Kudo, 2017 #292),[9](#_ENREF_9)]. Programmed cell-death protein 1 (PD-1) is one of the highly expressed immune checkpoints on T-cells in most solid tumours[[10](#_ENREF_10" \o "Kamphorst, 2013 #295)]. PD-1 was originally described by Ishida *et al*[11] in 1992 as a cell death inducer, a discovery that paved the way for Noble prize winning immune checkpoint inhibitor studies in 2018. Tumour immune surveillance evasion can then occur upon engagement of PD-1 with its ligand, Programmed death ligand 1 (PD-L1), expressed on tumour cells leading to effector T-cell exhaustion and dysfunction[[12](#_ENREF_12" \o "Wei, 2018 #6),[13](#_ENREF_13)]. PD-1/PD-L1 immune checkpoint blockade has shownconsiderable survival benefits in patients with different metastatic tumours[[14-17](#_ENREF_14" \o "Whiteside, 2016 #62)]. In 2017, the Food and Drug Administration approved Nivolumab, a human immunoglobulin G monoclonal antibody against PD-1, for patients with advanced HCC, due to durable responses observed in these patients[[18](#_ENREF_18" \o "El-Khoueiry, 2017 #67)].

Accumulating evidence has shown that PD-1/PD-L1 immune checkpoint is epigenetically regulated through immunomodulatory non-coding ribonucleic acids (ncRNAs) as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in several cancers including colorectal cancer[[19](#_ENREF_19" \o "Zhao, 2016 #194)], lung cancer[[20](#_ENREF_20)] and pancreatic cancer[[21](#_ENREF_21)]. Furthermore, our research group demonstrated the epigenetic regulation of PD-1/PD-L1 in breast cancer[[22](#_ENREF_22" \o "Salama, 2020 #1)]. Nevertheless, such immunomodulatory loops orchestrating PD-1/PD-L1 expression and activity are still under investigation in HCC.

Due to the breakthrough established in next generation sequencing which enabled the profiling of the whole transcriptomic expression at the molecular level, our understanding of biological systems has improved[[23](#_ENREF_23" \o "Koduru, 2017 #302)]. Such studies have revealed the expression deregulation of a multitude of ncRNAs[[24](#_ENREF_24" \o "Klingenberg, 2017 #3)].

Based on bioinformatics analysis, the miRNAs, oncomiR and miR-155-5p, and tumor suppressor miR-194-5p were predicted to target PD-L1 transcriptome as well as the candidate lncRNAs, X-inactive specific transcript (XIST) and MALAT-1. Moreover, lncRNAs XIST and MALAT-1 were predicted to target PD-L1 transcript where both lncRNAs have demonstrated their role in HCC pathogenesis in several studies.

Therefore, it is interesting to study the expression profile of PD-L1 in Huh-7 cells relative to the expression manipulation of candidate ncRNAs in order to explore novel potential upstream regulatory ncRNAs for PD-L1 in HCC and the capacity of these ncRNAs as therapeutic targets. In addition, it is of value to determine the clinical relevance of the proposed regulatory signaling pathways for PD-L1 in HCC patients by assessing the expression pattern of PD-L1 as well as the lncRNAs XIST and MALAT-1 in HCC tissues.

The trend towards integrating phytochemicals in cancer therapy is being augmented worldwide, especially with increased tolerance and resistance to traditional cancer therapeutic modalities. The olive tree (*Olea europaea L*.) which belongs to the Oleacaea family is native to tropical and warm temperate regions[[25](#_ENREF_25" \o "Ghanbari, 2012 #183)]. Several studies have postulated that the olive plant has anti-inflammatory[[26](#_ENREF_26" \o "Lockyer, 2015 #217)] and anti-cancer activities[[27](#_ENREF_27)]. Such activities are mainly attributed to the unique polyphenolic content of the olive plant.

Oleuropein is one of the highly abundant phenolic compounds in olive leaves[[28](#_ENREF_28" \o "Goldsmith, 2018 #9)]. It is reported to have a plethora of beneficial health benefits that are attributed to a compilation of pharmacological action including anti-oxidant[[29](#_ENREF_29" \o "Rizzo, 2017 #223)], anti-inflammatory[[30](#_ENREF_30)], and anti-angiogenic[[31](#_ENREF_31)] activities which pave the way for its interesting anticancer activity[[32](#_ENREF_32)]. Oleuropein has been demonstrated to have an anti-inflammatory and immunomodulatory effect *via* down-regulation of MAPKs and NF-κB signaling pathways as well as controlling the production of inflammatory mediators such as IL-6 and TNF-α cytokines, MMP-1 and MMP-3 levels[[33](#_ENREF_33" \o "Castejon, 2017 #239)]. Interestingly, Ruzzolini *et al*[[34](#_ENREF_34" \o "Ruzzolini, 2018 #3)] revealed the promising potential of oleuropein as an adjuvant therapy against BRAF melanoma, by manipulating the pAKT/pS6 pathway. Moreover, a recent study demonstrated the potential indirect modulatory impact of oleuropein on PD-L1 in esophageal cancer, by manipulating the expression of hypoxia-inducible factor-1[[35](#_ENREF_35)]. Nevertheless, to the best of our knowledge, the immunomodulatory impact of oleuropein on HCC has not been extensively studied. Hence, the impact of this promising compound on our study key players was determined.

**MATERIALS AND METHODS**

***Bioinformatics analysis***

To detect possible microRNAs targeting 3’UTR of PD-L1 mRNA, microrna.org ([www.microrna.org](http://www.microrna.org)) bioinformatics target prediction software was used. Based on the binding scores and number of hits, miRNAs with good scores were chosen. Diana tools software (<http://carolina.imis.athena-innovation.gr>) was used to analyze potential binding of miR-194 and miR-155 to the 3’UTR region of lncRNAs XIST and MALAT1. The [lnCeDB (Database of Human Long Noncoding RNA Acting as Competing Endogenous RNA](https://www.lncrnablog.com/Lncedb-database-of-human-long-noncoding-rna-acting-as-competing-endogenous-rna/)) prediction software algorithm ([www.http://gyanxet-beta.com/Lncedb](http://www.http/gyanxet-beta.com/Lncedb)) was used to analyze potential binding of lncRNA XIST and MALAT-1 to PD-L1.

***Patients and tissue samples***

The present study included 23 patients with HCC, who underwent liver transplant surgery in the Kasr El Einy Hospital (Cairo University, Cairo, Egypt). Four samples of cirrhotic tissues were taken from a subset of these patients with focal HCC lesions. As per the pathology report of these patients, summarized in Table 1, almost 70% of patients had > 1 focal lesion. Ten liver biopsies were obtained from healthy donors. Ethical approval for this study was issued by the Institutional Review Board of Cairo University. In addition, all participants provided written informed consent. The institutional ethics committees approving this research comply with the principles set forth in the international reports and guidelines of the Helsinki Declaration and the International Ethical Guidelines for Biomedical Research Involving Human Subjects, issued by the Council for International Organizations of Medical Sciences.

***Cell culture***

Huh-7 cells were purchased from Vacsera Egypt. They were maintained in Dulbecco's modified Eagle's medium (DMEM, Lonza, Germany, cat. no. 12-604F), supplemented with 4.5 g/L glucose, 4 mmol/L L-glutamine, 10% fetal bovine serum (Applied Biosystems; Thermo Fisher Scientific Inc., cat. no. 10270098) and Mycozap (1:500; Lonza, cat. no. LT07-818) at 37°C in a 5% carbon dioxideatmosphere.

***Transfection of miR and siRNAs oligonucleotides***

Twenty-four hours prior to transfection, 1-5 × 104 or 2-8 × 104 Huh-7 cells (40%-80% confluency) per well were seeded in a 96-well plate or 24-well plate, respectively. The cells were incubated under normal growth conditions (37°C and 5% carbon dioxide). The Huh-7 cell line was transfected with miScript™ miRNA mimics/inhibitors of miR-155-5p (Syn-hsa-miR-155-5p miScript miRNA Mimic, Qiagen, cat. no. MSY0000646 and Anti-hsa-miR-155-5p miScript miRNA Inhibitor, Qiagen, cat. no. MIN0000646) and miR-194 (Syn-hsa-miR-194-5p miScript miRNA Mimic, Qiagen, cat. no. MSY0000460 and Anti-hsa-miR-194-5p miScript miRNA Inhibitor, Qiagen, cat. no. MIN0000460). Transfections with siRNAs for each of XIST (Hs\_XIST\_3 FlexiTube siRNA, Qiagen Germany, cat. no. SI03654483), the negative regulator of X-inactive specific transcript (TSIX), (Hs\_TSIX\_7 FlexiTube siRNA, Qiagen Germany, cat. no. SI04708795) and MALAT-1 (Hs\_MALAT1\_1 FlexiTube siRNA, Qiagen Germany, cat. no. SI03670541) were also carried out. Co-transfections of each of the miR-155 and miR194 mimics were carried out with the siRNAs of each of the three lncRNAs MALAT-1, XIST and TSIX, respectively. All transfection experiments were performed in triplicate using HiPerfect Transfection Reagent (Qiagen Germany, cat. no. 301705) according to the manufacturer's instructions, and experiments were repeated three times. Cells that were exposed only to the transfection reagent were designated mock cells; cells transfected with miR-155 or miR-194 mimics were designated miR-155 cells and miR-194 cells, respectively; cells transfected with the miR-155 or miR-194 inhibitors were designated as anti-miR-155 cells and anti-miR-194 cells, respectively; cells transfected with XIST siRNAs were designated as XIST siRNA cells; cells transfected with MALAT-1 siRNAs were designated as MALAT-1 siRNA cells; cells transfected with TSIX siRNAs were designated as TSIX siRNA cells; cells co-transfected with miR-155 and XIST siRNA were designated as miR-155/siXIST; cells co-transfected with miR-155 and MALAT-1siRNA were designated as miR-155/siMALAT-1; cells co-transfected with miR-155 and TSIX siRNA were designated as miR-155/siTSIX; cells co-transfected with miR-194 and XIST siRNA were designated as miR-194/siXIST; cells co-transfected with miR-194 and MALAT-1 siRNA were designated as miR-194/siMALAT-1; cells co-transfected with miR-194 and TSIX siRNA were designated as miR-194/siTSIX; Cells were lysed 48 h post-transfection and total RNA was extracted for further analysis.

***Plant material and fractionation***

Olive leaves were collected from northern Sinai, Egypt and authenticated by Mrs. Therasa Labib, Taxonomist, Orman Botanical Garden, Egypt. Voucher specimen number (00396) was deposited at the Herbarium of the Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo. Exhaustive extraction of olive leaves was carried out using 70% aqueous-ethanol, followed by re-suspension of the residue in H2O and fractionation against petroleum ether, chloroform and ethyl acetate to yield 17 g, 6.5 g and 4.5, g respectively. The ethyl acetate polar fraction was applied over an open column (64 cm L × 5.5 cm ID) packed with silica (250 g) as stationary phase. A CHCl3:CH3OH:H2O gradient was used for the elution process to ensure purification of the sub-fractions.

***Isolation of oleuropein***

The sub-fraction of interest (30 mg) was obtained using CHCl3:CH3OH:H2O in a ratio of 3:4:3, then injected into a preparative high performance liquid chromatograph (Waters 600 E multisolvent delivery system, Waters 600 E pump and Waters 2998 PDA) which was employed using Lichrospher 100 RP-18 (250 mm × 10 mm i.d.; 10 µm) (Merck KGaA, Darmstadt, Germany). The mobile phase used was composed of 0.2% H3PO4 (v/v), methanol and acetonitrile in a ratio of 96:2:2. NMR spectra were obtained using a Bruker Avance 500 spectrometer (Bremen, Germany) 5 mm-Zgrad probe, operating at 500.13 MHz for 1H and 125.77 MHz for 13C. The purity of oleuropein was confirmed using analytical HPLC (Agilent Technologies, Waldbronn, Germany), equipped with a PDA detector G 1314 C (SL). Chromatographic separation was carried out on a Superspher 100 RP-18 (75 mm × 4 mm i.d.; 4 μm) column (Merck, Darmstadt, Germany) using mobile phases: (A) 2% acetic acid (pH 2.6) and (B) 80% methanol. A gradient starting from 5% B to 50% B was employed for the elution process with 100 μL/min flow rate at 30°C and compared *vs* standard material (Sigma Aldrich) using HPLC. Confirmation of oleuropein identity was carried out by comparing its spectral data to the obtained literature[[36](#_ENREF_36" \o "Olmo-Cunillera, 2020 #2)].

***Oleuropein treatment to HuH-7 cells***

A stock solution of oleuropein 100 mmol/L was prepared by dissolving 0.108 g in 2 mL of free DMEM. A solution of 80 µmol/L concentration that was previously reported as LC50 on Huh-7 cells[[37](#_ENREF_37" \o "Yan, 2015 #236)] was prepared using this stock.

***RNA isolation from liver biopsies and Huh-7 cell line***

RNA was isolated from Huh-7 cells and liver biopsies using the TRIzol™ LS Reagent (Applied Biosystems; Thermo Fisher Scientific Inc., cat. no. 10296010) extraction protocol.

***Quantified real-time polymerase chain reaction***

Total RNA extracted was reverse-transcribed into single-stranded complementary DNA (cDNA) using the high-capacity cDNA reverse transcription kit (Applied Biosystems; Thermo Fisher Scientific Inc., cat. no. 4368814). The relative expression of miR-155 as well as miR-194 to that of RNU6B (housekeeping gene), in addition to PD-L1 mRNA, XIST and MALAT-1 lncRNAs to that of β-2-microglobulin (β2M; a housekeeping gene) were quantified with TaqMan RT-quantitative polymerase chain reaction [quantified real-time polymerase chain reaction (qRT-PCR); Applied Biosystems Assay IDs: 002287, 000493, 0001093, Hs01079824\_m1, Hs00273907\_ml and Hs00984230\_m1 and Hs01060665\_g1, respectively] using StepOne™ Systems (Applied Biosystems Life Technologies). The PCR for miR quantification included 1 µL TaqMan Small RNA Assay (20 X) specific for each of miR-155 or miR-194 or RNU6B and 1.33 µL cDNA from each miR-155 or miR-194 or RNU6B RT reactions, respectively. Taqman target gene assay expression assay (1 µL) specific for each of PD-L1, XIST and MALAT-1 as well as 4 µL of the respective cDNA were used for quantification. The RT-qPCR run was performed in the standard mode, consisting of two stages: A first 10 min stage at 95°C where the Taq-polymerase enzyme was activated, followed by a second stage of 40 amplification cycles (15 s at 95°C and 60 s at 60°C). Relative expression was calculated using the 2−ΔΔCq method. All PCR reactions, including controls, were run in triplicate.

***Statistical analysis***

All data were expressed in relative quantitation. For the purpose of comparison between two different studied groups, the Student's unpaired *t*-test was used. Data were expressed as mean ± SD error of the mean. A *p* value less than 0.05 was considered statistically significant. d*P* < 0.0001, c*P* < 0.001, b*P* < 0.01, a*P* < 0.05. Analysis was performed using GraphPad Prism 7.02.

**RESULTS**

***In silico analysis***

According to miRANDA software and the miRDB database, a total of 146 miRNAs were predicted to target PD-L1 mRNA. Both miR-155 and miR-194 were predicted to bind to the 3’UTR region of PD-L1 mRNA using miRANDA software and Targetscan software, while binding of miR-194 and miR-155 to the 3’UTR region of lncRNAs XIST and MALAT1 was predicted using Diana tools software. MALAT1 and XIST were predicted to target PD-L1 mRNA according to LnCeDB software algorithms.

***Expression profile of PD-L1 in liver tissues***

The expression profile of PD-L1 was assessed in HCC patients, and adjacent cirrhotic biopsies in a subset of patients together with 10 donor healthy controls, using qRT-PCR. PD-L1 was significantly elevated in both HCC biopsies (*P* = 0.0065) and cirrhotic biopsies (*P* = 0.0251) in comparison to healthy controls (Figure 1).

***Expression profile of lncRNAs; XIST and MALAT-1 in HCC tissues***

The expression profile of the endogenous lncRNAs XIST and MALAT-1 was examined in HCC patients and adjacent cirrhotic biopsies in a subset of patients together with 10 healthy donors using qRT-PCR. HCC patients showed a significant upregulation of XIST expression (*P* = 0.048) compared to healthy controls. MALAT-1 expression in HCC patients was barely detected (*P* = 0.043) and a significant upregulation was found in the cirrhotic tissues (*P* = 0.0136) (Figure 2).

***Manipulation of endogenous miR-194-5p and miR-155-5p expression in Huh-7 cells.***

**Transfection efficiency of miR-194-5p and miR-155-5p oligonucleotides:**In order to manipulate the expression of miR-194-5p and miR-155-5p in Huh-7 cells, the cells were transfected with each of the respective miRNA mimics and antagomirs, respectively. Efficient transfection was assessed 48 h post-transfection using qRT-PCR, and both miR-194-5p (Figure 3A) and miR-155-5p (Figure 3B) were markedly increased in mimicked cells compared to mock cells, (*P* = 0.0026) and (*P* < 0.0001), respectively.

**Impact of miR-194-5p and miR-155-5p on PD-L1 transcript expression in Huh-7 cells:** Mimicking of both miRNAs miR-155 and miR-194 in Huh-7 cells showed an up-regulation of PD-L1 expression (*P* = 0.0219) (*P* = 0.0209), respectively, compared to the mock untransfected cells (Figure 4). However, antagonizing both miRNAs resulted in a significant downregulation of PD-L1 transcript expression compared to mock untransfected cells.

**Impact of miR-155-5p and miR-194-5p on lncRNAs XIST and MALAT-1 expression in Huh7 cells:** Following ectopic expression manipulation of each of the respective miRNAs in Huh-7 cells, the lncRNAs XIST and MALAT-1 expression profiles were assessed using qRT-PCR and normalized to B2M an endogenous housekeeping gene. (A) Mimicking of miR-194-5p and miR-155-5p resulted in an upregulated expression profile of XIST compared to the mock untransfected cells, (*P* = 0.0026, *P* = 0.0477), respectively, as shown in Figure 5A; (B) Meanwhile, as shown in Figure 5B, mimicking of miR-194-5p and miR-155-5p had a paradoxical impact on the MALAT-1 expression profile. Mimicking of miR-194-5p induced the expression of MALAT-1 (*P* = 0.0135) compared to mock untransfected cells. On the other hand, mimicking of miR-155-5p induced the downregulation of MALAT-1 expression compared to mock untransfected cells (*P* = 0.0053).

***Impact of knocking down the lncRNAs MALAT-1, XIST and TSIX on PD-L1 expression in Huh-7 cells***

Knockdown of MALAT-1 significantly down regulated PD-L1 expression (*P* = 0.001) compared to mock cells. On the other hand, transfection with siRNAs of TSIX induced the upregulation of PD-L1 expression (*P* = 0.0358) compared to mock cells. Knockdown of XIST resulted in an insignificant change in the PD-L1 expression profile compared to untransfected mock cells (Figure 6).

***Net impact of combined ectopic expression of miR-194-5p and miR-155-5p together with siRNAs of lncRNAs XIST, TSIX and MALAT-1 on PD-L1 expression profile.***

The expression profile of PD-L1 transcript was studied following co-transfection of Huh-7 cells with different combinations of each miRNA; miR-194-5p and miR-155-5p, respectively, with each of the siRNAs of lncRNAs; MALAT-1, XIST and TSIX. Values were normalized to the endogenous housekeeping gene B2M and compared to mock untransfected cells. Following transfection of miR-194-5p with siRNA of MALAT-1, PD-L1 expression was significantly induced (*P* = 0.0074). However, following knockdown of XIST, miR-194-5p did not have a significant impact on PD-L1 expression compared to mock cells. However, co-transfection of miR-194-5p with siRNA TSIX, did have a positive impact on the PD-L1 expression profile compared to mock cells (*P* = 0.0067). Co-transfection of miR-155-5p siRNA MALAT-1 showed a significant upregulation of the PD-L1 transcript expression (*P* = 0.0060). However, miR-155-5P was unable to elevate PD-L1 expression following knockdown of XIST as there was no significant change in PD-L1 expression compared to mock cells. Knockdown of TSIX and co-transfection with miR-155-5P significantly induced the expression of PD-L1 (*P* = 0.0188) (Figure 7).

***Impact of oleuropein on the study key players; PD-L1 transcript, miR-194-5p and miR-155-5p and lncRNAs MALAT-1 and XIST***

Treatment of Huh-7 cells with pure isolated oleuropein showed surprising results (Figure 8). Oleuropein treatment significantly downregulated the expression of PD-L1 (*P* = 0.0011), XIST (*P* = 0.0020) and miR-155 (*P* = 0.0001); however, MALAT-1 expression profile was not affected following oleuropein treatment. The miR-194-5p expression pattern was upregulated following oleuropein treatment (*P* = 0.0022).

**DISCUSSION**

The high expression pattern of immune checkpoints is a major cause of inefficient anti-tumor immunity. In this framework, immune checkpoint blockade has been revitalized to unleash the potential of anti-tumor immunity[[38](#_ENREF_38" \o "Pardoll, 2012 #10)]. Nevertheless, immunotherapeutic approaches have modest responses in HCC. Thus, combinatorial therapeutic strategies including epigenetic modulation through ncRNAs and immunomodulation techniques are implemented to circumvent the limitation of immunotherapeutic techniques[[39](#_ENREF_39" \o "Hong, 2019 #1)]. Recently, a novel interaction circuit has been demonstrated in the competing endogenous RNA (ceRNAs) network, composed of three RNAs “lncRNA-miRNA-mRNA”. Here, we showed that PD-L1 in HCC is a member of a ceRNA network orchestrated by miR-155, miR-194 and lncRNA XIST.

Based on in-silico analysis, the oncogenic miR-155-5p and tumour suppressor miR-194-5p were predicted to target PD-L1 mRNA. It has been postulated that miR-155 promotes tumorigenic properties in HCC-derived cell lines and hence is an oncogenic miRNA in HCC pathogenesis[[40-42](#_ENREF_40" \o "Xin‐Long, 2013 #72)]. On the other hand, miR-194 has tumour suppressor activity in HCC as it was downregulated in HCC biopsies[[43-45](#_ENREF_43" \o "Zhao, 2015 #76)]. Interestingly, a paradoxical function of the tumour suppressor miR-194-5p in HCC was revealed in this study, and was able to elevate the abundance of the oncogenic mediator, PD-L1. Similarly, another study demonstrated the contradictory role of the oncomiR miR-125b in hematological malignancies, in which its oncogenic activity could be overcome in some instances in chronic lymphocytic leukemia to act as a tumour suppressor[[46](#_ENREF_46" \o "Svoronos, 2016 #203)].

Inspired by the ceRNA regulatory network, we investigated the impact of the key miRNAs players on the proposed lncRNAs. Bioinformatics analysis was adopted to predict the potential lncRNAs targeted by miR-194-5p and miR-155-5p. Based on the literature, two lncRNAs were selected, XIST and MALAT-1. LncRNA XIST is reported to be an oncogenic RNA as it is associated with worsening of survival in HCC patients, in which its oncogenic activity is mediated by AKt signaling pathway activation through the miR-139-5p/PDK1 axis[[47](#_ENREF_47" \o "Mo, 2017 #154)]. Nevertheless, overexpression of miR-194-5p and miR-155-5p induced an elevation in XIST. This finding also confirms the potential paradoxical role of miR-194-5p in HCC pathogenesis.

Several studies have shown upregulation of MALAT-1 in HCC biopsies[[48](#_ENREF_48" \o "Guerrieri, 2015 #165),[49](#_ENREF_49)]. However, one study reported that following MALAT-1 knockdown in a hepatoma cell line, no variations in the proliferation pattern, cell cycle progression or nuclear architecture were observed[[50](#_ENREF_50" \o "Eißmann, 2012 #159)]. Surprisingly, overexpression of miR-194-5p induced the elevation of MALAT-1. In contrast, induced expression of miR-155-5p resulted in downregulation of MALAT-1. Taken together, these findings demonstrate the paradoxical functions of miRNAs in tumours, in which miR-194-5p expression induction elevated the expression of oncogenic members in the Huh-7 cell line. A plausible explanation for this anomaly is the fact that a single miRNA can target tens to hundreds of mRNAs, some of which are tumour suppressors and others are oncogenes. According to the balance in expression of the targeted mRNAs, a net effect of oncogenic or tumour suppressor activity can emerge[[46](#_ENREF_46" \o "Svoronos, 2016 #203)].

Our study showed that knockdown of MALAT-1 using siMALAT-1 resulted in downregulation of PD-L1 transcript. On the other hand, following knockdown of XIST negative regulator, TSIX, PD-L1 transcript was significantly elevated. These findings are considered to be helpful in clarifying the interesting role of tumour-suppressor miR-194-5p in elevating PD-L1, an activity that could be mediated through XIST and MALAT-1. However, the role of MALAT-1 in PD-L1 transcript elevation in HCC is still questionable, as despite the downregulation of MALAT-1 upon miR-155-5p overexpression, PD-L1 transcript was found to be highly abundant.

In order to have a full understanding of the ceRNA network involved in PD-L1 transcript level modulation in HCC, the combined effect of the respective miRNAs and lncRNAs on PD-L1 transcript abundance was studied. MiR-194-5p elevated PD-L1 transcript abundance even in the absence of MALAT-1. However, when XIST was knocked down, miR-194-5p was unable solely to affect PD-L1 abundance level. Nevertheless, upon XIST upregulation together with mimicking of miR-194-5P, PD-L1 transcript level was restored. These findings provide solid evidence of the pivotal role of XIST in increased PD-L1 transcript abundance. Surprisingly, similar findings were observed following co-transfection of miR-155-5p mimics with each of the siRNAs of the respective lncRNAs, comparable to their co-transfection with miR-194-5p. These findings provide extra proof of the insignificant role of MALAT-1 in the PD-L1 expression pattern in comparison with XIST and both respective miRNAs.

The *in-vitro* results of our study also demonstrated the dual activity of miR-194-5p. Based on the literature, miR-194-5p has tumour suppressor activity in HCC by exerting a negative impact on cell viability and proliferation[[43](#_ENREF_43" \o "Zhao, 2015 #76)]. However, our results indicated that overexpression of miR-194-5p increased the abundance of the two oncogenic HCC members PD-L1 and XIST similar to the impact of oncogenic miR-155-5p. Hence, our next aim was to determine the results *ex-vivo* by screening HCC biopsies for PD-L1, XIST and MALAT-1 expression. An elevated expression of XIST in HCC biopsies was noted which was in accordance with several other studies that have reported the oncogenic role of XIST in HCC[[47](#_ENREF_47" \o "Mo, 2017 #154),[51](#_ENREF_51)]. Also, PD-L1 was found to be significantly overexpressed in HCC biopsies compared to normal donor biopsies. This result is similar to that in other studies which reported the elevated expression of PD-L1 in HCC and its mechanistic role in immune evasion[[52](#_ENREF_52" \o "Ohaegbulam, 2015 #214)]. To our surprise, MALAT-1 was barely detected in HCC biopsies, in contrast to other studies that have reported the oncogenic role of MALAT-1 in HCC[[53](#_ENREF_53" \o "Liu, 2017 #215)]. The interesting finding of downregulated MALAT-1 in HCC biopsies is in accordance with the *in-vitro* finding of the insignificant role of MALAT-1 in PD-L1 expression in HCC cells.

This study highlights the potential therapeutic targets in HCC including the members of the aforementioned upstream regulatory pathways of PD-L1. Nevertheless, the clinical application of ncRNAs as therapeutics is still limited and understudied. Thus, a trend towards using nutraceuticals in cancer therapy has developed due to the feasibility of their clinical application[[54](#_ENREF_54" \o "Zhu, 2016 #241)]. Phytochemicals did not only demonstrate epigenetic immunomodulation by targeting lncRNAs and miRNAs, but have also revealed their role in immune checkpoint modulation[[55](#_ENREF_55" \o "Coombs, 2016 #238)].

Due to the favorable role of polyphenolic nutraceuticals in epigenetic modulation, the nutraceutical oleuropein was selected for this study in order to determine its impact on the study key players, based on its aforementioned anti-inflammatory and immunomodulatory effects[[33](#_ENREF_33" \o "Castejon, 2017 #239)].

At 80 µmol/L[[37](#_ENREF_37" \o "Yan, 2015 #236)], oleuropein significantly reduced the abundance of PD-L1 in Huh-7 cells. When the abundance of potential upstream regulatory ncRNAs was measured, it was found that XIST expression was significantly down regulated. However, oleuropein did not have a significant impact on MALAT-1 expression. Measurement of the impact of oleuropein on miR-194-5p and miR-155-5p revealed that miR-194-5p expression was markedly upregulated. In contrast, miR-155-5p was significantly downregulated. This finding is in accordance with another study that reported the negative impact of oleuropein on miR-155 in a breast cancer cell line, which manifested anti-proliferative, apoptotic, and anti-metastatic effects in the breast cancer cell line[[56](#_ENREF_56" \o "Maryam, 2018 #234)]. Finally, the potential of oleuropein as a therapeutic agent in HCC requires further investigation in order to support these promising findings.

Some limitations must be acknowledged in this study. First, the limited number of patients and subsequently, number of tissue biopsies; however, statistically significant results were obtained. Further studies using a larger number of tissue biopsies should be performed to validate the proposed pathway in a larger cohort of patients. Second, a further robust study design is necessary to analyze the study key players in peripheral blood samples of advanced HCC patients and to investigate the impact of mimicking the miRNAs, miR-155-5p and miR-194-5p, on PD-L1 protein levels in HCC cell lines.

**CONCLUSION**

In conclusion, this study reported the controversial role of miR-194-5p in HCC as it has the paradoxical function of being both a tumour suppressor and oncogenic activity in HCC, and had the same impact on upregulation of PD-L1 and XIST. Transfection of each of the siRNAs of the respective lncRNAs, showed that XIST and MALAT-1 can have a positive impact on PD-L1 transcript abundance. However, following a series of co-transfections, it was demonstrated that XIST is a cornerstone in PD-L1 expression, while MALAT-1 has no significant impact compared to the respective miRNAs and XIST. Thus, a novel shared upstream regulatory signaling pathway for PD-1/PD-L1 immune checkpoint paradoxically acting on miR-194-5p and miR-155-5p occurs, through XIST expression modulation (Figure 9). Thus, the key regulators of the ceRNA circuit could be employed as therapeutic targets in HCC.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatocellular carcinoma (HCC) develops in an inflammatory milieu containing tumor infiltrating lymphocytes, thus boosting tumor immunogenicity and provides an aspect for developing immunotherapies against HCC. However, immunotherapies have a modest response in HCC, accordingly combinatorial therapies with epigenetic immunomodulation may be a promising modality. Growing scientific evidence has suggested a modulatory role for miRNAs and long non-coding ribonucleic acids (lncRNAs) on programmed cell-death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint in HCC.

***Research motivation***

HCC is considered a therapy-resistant disease, and is frequently diagnosed at an advanced stage. Thus, the development of a novel therapeutic modality is essential. It is noteworthy that immune checkpoint blockade therapy in HCC is gaining attention. Additionally, given the wide range of non-coding RNAs (ncRNAs) that orchestrate PD-1/PD-L1 immune checkpoint, we investigated how selected ncRNAs regulate PD-1/PD-L1 immune checkpoint. Hence, the therapeutic potential of combining epigenetic immunomodulation through ncRNAs with immune checkpoint blockade was studied.

***Research objectives***

This study aimed at exploring potential upstream regulatory ncRNAs of immune checkpoint PD-1/PD-L1. Hence, the potential of combining immune checkpoint blockade with epigenetic immunomodulation was investigated.

***Research methods***

Based on bioinformatics software and the literature, ncRNAs including miR-155-5p and miR-194-5p as well as lncRNAs X-inactive specific transcript (XIST) and MALAT-1 were selected. 23 HCC tissue biopsies and 10 healthy donor tissue biopsies were used to screen the expression of PD-L1 as well as lncRNAs XIST and MALAT-1. To study the interaction between miR-155-5p, miR-194-5p, lncRNAs XIST and MALAT-1, as well as PD-L1 mRNA, a series of transfections and co-transfections of the Huh-7 cell line was carried out. Quantified real-time polymerase chain reaction was then utilized to study the abundance of selected ncRNAs as well as PD-L1 transcripts in Huh-7 cells in the transfections experiments.

***Research results***

Based on bioinformatics software and the literature, we hypothesized that a potential upstream regulatory pathway to immune checkpoint PD-L1 is present in HCC, composed of both miRNAs, tumor suppressor miR-194-5p and oncomiR-155-5p, as well as both lncRNAs XIST and MALAT-1. Following the screening of 23 HCC biopsies, PD-L1 and XIST were found to be significantly upregulated compared to healthy controls; however, MALAT-1 was barely detected. Induced expression of miR-194-5p and miR-155-5p in the Huh-7 cell line showed the same pattern of upregulation of both PD-L1 transcript and XIST. However, ectopic expression of the respective miRNAs had a paradoxical impact on MALAT-1 abundance, *i.e.* miR-194-5p induced the upregulation of MALAT-1 while miR-155-5p downregulated the abundance of MALAT-1. Knockdown of XIST had no impact on PD-L1 expression; however, following knockdown of the negative regulator of X-inactive specific transcript (TSIX), PD-L1 expression was elevated, and MALAT-1 activity was abolished. Upon co-transfection of miR-194-5p with siMALAT-1, PD-L1 expression was elevated. On the other hand, co-transfection of miR-194-5p with siXIST did not have an impact on PD-L1 expression. Following co-transfection of miR-194 with siTSIX, PD-L1 expression was upregulated. Interestingly, the same PD-L1 expression pattern was revealed following the oncomiR-155-5p co-transfection series.

***Research conclusions***

In conclusion, this study reported the controversial role of miR-194-5p in HCC and despite its paradoxical function of a tumour suppressor and having oncogenic activity in HCC, both had the same impact on upregulation of XIST. LncXIST is thought to be an intermediate player whose upregulation increased PD-L1 transcript abundance.

***Research perspectives***

Although further investigations are needed, this study proposes a novel competing endogenous RNA circuit made up of both miR-155-5p and miR-194-5p as well as lncXIST and PD-L1 mRNA. This circuit could be regarded as a potential therapeutic target in HCC.

**REFERENCES**

1 **Yang JD**, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 589-604 [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y]

2 **Llovet JM**, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. *Nat Rev Clin Oncol* 2015; **12**: 408-424 [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103]

3 **Llovet JM**, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. *Nat Rev Clin Oncol* 2018; **15**: 599-616 [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4]

4 **Xie Y**, Xiang Y, Sheng J, Zhang D, Yao X, Yang Y, Zhang X. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. *J Immunol Res* 2018; **2018**: 8740976 [PMID: 29785403 DOI: 10.1155/2018/8740976]

5 **Ji J**, Yin Y, Ju H, Xu X, Liu W, Fu Q, Hu J, Zhang X, Sun B. Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. *Cell Death Dis* 2018; **9**: 478 [PMID: 29706626 DOI: 10.1038/s41419-018-0528-7]

6 **Flecken T**, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. *Hepatology* 2014; **59**: 1415-1426 [PMID: 24002931 DOI: 10.1002/hep.26731]

7 **Mellman I**, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature* 2011; **480**: 480-489 [PMID: 22193102 DOI: 10.1038/nature10673]

8 **Kudo M**. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. *Oncology* 2017; **92 Suppl 1**: 50-62 [PMID: 28147363 DOI: 10.1159/000451016]

9 **Okazaki T**, Honjo T. The PD-1-PD-L pathway in immunological tolerance. *Trends Immunol* 2006; **27**: 195-201 [PMID: 16500147 DOI: 10.1016/j.it.2006.02.001]

10 **Kamphorst AO**, Ahmed R. Manipulating the PD-1 pathway to improve immunity. *Curr Opin Immunol* 2013; **25**: 381-388 [PMID: 23582509 DOI: 10.1016/j.coi.2013.03.003]

11 **Ishida Y**, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J* 1992; **11**: 3887-3895 [PMID: 1396582]

12 **Wei SC**, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. *Cancer Discov* 2018; **8**: 1069-1086 [PMID: 30115704 DOI: 10.1158/2159-8290.CD-18-0367]

13 **Iwai Y**, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *Proc Natl Acad Sci* 2002; **99**: 12293-12297 [PMID: 12218188 DOI: 10.1073/pnas.192461099]

14 **Whiteside TL**, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging Opportunities and Challenges in Cancer Immunotherapy. *Clin Cancer Res* 2016; **22**: 1845-1855 [PMID: 27084738 DOI: 10.1158/1078-0432.CCR-16-0049]

15 **Weber JS**, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol* 2015; **16**: 375-384 [PMID: 25795410 DOI: 10.1016/S1470-2045(15)70076-8]

16 **Motzer RJ**, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015; **373**: 1803-1813 [PMID: 26406148 DOI: 10.1056/NEJMoa1510665]

17 **Sharma P**, Allison JP. The future of immune checkpoint therapy. *Science* 2015; **348**: 56-61 [PMID: 25838373 DOI: 10.1126/science.aaa8172]

18 **El-Khoueiry AB**, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; **389**: 2492-2502 [PMID: 28434648 DOI: 10.1016/S0140-6736(17)31046-2]

19 **Zhao L**, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, Shen S. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. *Oncotarget* 2016; **7**: 45370-45384 [PMID: 27248318 DOI: 10.18632/oncotarget.9659]

20 **Cortez MA**, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 Regulation by p53 via miR-34. *J Natl Cancer Inst* 2016; **108**: [PMID: 26577528 DOI: 10.1093/jnci/djv303]

21 **Yao K**, Wang Q, Jia J, Zhao H. A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer. *Tumour Biol* 2017; **39**: 1010428317707882 [PMID: 28639886 DOI: 10.1177/1010428317707882]

22 **Salama EA**, Adbeltawab RE, El Tayebi HM. XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. *Front Oncol* 2019; **9**: 1459 [PMID: 31998636 DOI: 10.3389/fonc.2019.01459]

23 **Koduru SV**, Tiwari AK, Leberfinger A, Hazard SW, Kawasawa YI, Mahajan M, Ravnic DJ. A Comprehensive NGS Data Analysis of Differentially Regulated miRNAs, piRNAs, lncRNAs and sn/snoRNAs in Triple Negative Breast Cancer. *J Cancer* 2017; **8**: 578-596 [PMID: 28367238 DOI: 10.7150/jca.17633]

24 **Klingenberg M**, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. *J Hepatol* 2017; **67**: 603-618 [PMID: 28438689 DOI: 10.1016/j.jhep.2017.04.009]

25 **Ghanbari R**, Anwar F, Alkharfy KM, Gilani AH, Saari N. Valuable nutrients and functional bioactives in different parts of olive (Olea europaea L.)-a review. *Int J Mol Sci* 2012; **13**: 3291-3340 [PMID: 22489153 DOI: 10.3390/ijms13033291]

26 **Lockyer S**, Corona G, Yaqoob P, Spencer JP, Rowland I. Secoiridoids delivered as olive leaf extract induce acute improvements in human vascular function and reduction of an inflammatory cytokine: a randomised, double-blind, placebo-controlled, cross-over trial. *Br J Nutr* 2015; **114**: 75-83 [PMID: 26051429 DOI: 10.1017/S0007114515001269]

27 **Boss A**, Bishop KS, Marlow G, Barnett MP, Ferguson LR. Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions. *Nutrients* 2016; **8**: [PMID: 27548217 DOI: 10.3390/nu8080513]

28 **Goldsmith CD**, Bond DR, Jankowski H, Weidenhofer J, Stathopoulos CE, Roach PD, Scarlett CJ. The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells. *Int J Mol Sci* 2018; **19**: [PMID: 30004416 DOI: 10.3390/ijms19071937]

29 **Rizzo M**, Ventrice D, Giannetto F, Cirinnà S, Santagati NA, Procopio A, Mollace V, Muscoli C. Antioxidant activity of oleuropein and semisynthetic acetyl-derivatives determined by measuring malondialdehyde in rat brain. *J Pharm Pharmacol* 2017; **69**: 1502-1512 [PMID: 28879679 DOI: 10.1111/jphp.12807]

30 **Qabaha K**, Al-Rimawi F, Qasem A, Naser SA. Oleuropein Is Responsible for the Major Anti-Inflammatory Effects of Olive Leaf Extract. *J Med Food* 2018; **21**: 302-305 [PMID: 29099642 DOI: 10.1089/jmf.2017.0070]

31 **Song H**, Lim DY, Jung JI, Cho HJ, Park SY, Kwon GT, Kang YH, Lee KW, Choi MS, Park JHY. Dietary oleuropein inhibits tumor angiogenesis and lymphangiogenesis in the B16F10 melanoma allograft model: a mechanism for the suppression of high-fat diet-induced solid tumor growth and lymph node metastasis. *Oncotarget* 2017; **8**: 32027-32042 [PMID: 28410190 DOI: 10.18632/oncotarget.16757]

32 **Shamshoum H**, Vlavcheski F, Tsiani E. Anticancer effects of oleuropein. *Biofactors* 2017; **43**: 517-528 [PMID: 28612982 DOI: 10.1002/biof.1366]

33 **Castejón ML**, Rosillo MÁ, Montoya T, González-Benjumea A, Fernández-Bolaños JG, Alarcón-de-la-Lastra C. Oleuropein down-regulated IL-1β-induced inflammation and oxidative stress in human synovial fibroblast cell line SW982. *Food Funct* 2017; **8**: 1890-1898 [PMID: 28426090 DOI: 10.1039/c7fo00210f]

34 **Ruzzolini J**, Peppicelli S, Andreucci E, Bianchini F, Scardigli A, Romani A, la Marca G, Nediani C, Calorini L. Oleuropein, the Main Polyphenol of *Olea europaea* Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies. *Nutrients* 2018; **10**: [PMID: 30544808 DOI: 10.3390/nu10121950]

35 **Zhang F**, Zhang M. Oleuropein inhibits esophageal cancer through hypoxic suppression of BTG3 mRNA. *Food Funct* 2019; **10**: 978-985 [PMID: 30702111 DOI: 10.1039/c8fo02223b]

36 **Olmo-Cunillera A**, López-Yerena A, Lozano-Castellón J, Tresserra-Rimbau A, Vallverdú-Queralt A, Pérez M. NMR spectroscopy: a powerful tool for the analysis of polyphenols in extra virgin olive oil. *J Sci Food Agric* 2020; **100**: 1842-1851 [PMID: 31802495 DOI: 10.1002/jsfa.10173]

37 **Yan CM**, Chai EQ, Cai HY, Miao GY, Ma W. Oleuropein induces apoptosis via activation of caspases and suppression of phosphatidylinositol 3-kinase/protein kinase B pathway in HepG2 human hepatoma cell line. *Mol Med Rep* 2015; **11**: 4617-4624 [PMID: 25634350 DOI: 10.3892/mmr.2015.3266]

38 **Pardoll DM**. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012; **12**: 252-264 [PMID: 22437870 DOI: 10.1038/nrc3239]

39 **Hong YK**, Li Y, Pandit H, Li S, Pulliam Z, Zheng Q, Yu Y, Martin RCG. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. *Cell Immunol* 2019; **336**: 66-74 [PMID: 30626493 DOI: 10.1016/j.cellimm.2018.12.010]

40 **Yan XL**, Jia YL, Chen L, Zeng Q, Zhou JN, Fu CJ, Chen HX, Yuan HF, Li ZW, Shi L, Xu YC, Wang JX, Zhang XM, He LJ, Zhai C, Yue W, Pei XT. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. *Hepatology* 2013; **57**: 2274-2286 [PMID: 23316018 DOI: 10.1002/hep.26257]

41 **Xie Q**, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA, Zhuang H. Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. *Cancer* 2012; **118**: 2431-2442 [PMID: 21989846 DOI: 10.1002/cncr.26566]

42 **El Tayebi HM**, Waly AA, Assal RA, Hosny KA, Esmat G, Abdelaziz AI. Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. *Oncol Lett* 2015; **10**: 3206-3212 [PMID: 26722313 DOI: 10.3892/ol.2015.3725]

43 **Zhao Y**, Li F, Zhang X, Liu A, Qi J, Cui H, Zhao P. MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4. *Int J Clin Exp Pathol* 2015; **8**: 12446-12454 [PMID: 26722431]

44 **Bao C**, Li Y, Huan L, Zhang Y, Zhao F, Wang Q, Liang L, Ding J, Liu L, Chen T, Li J, Yao M, Huang S, He X. NF-κB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by suppressing the transcription factor HNF-1α. *Sci Signal* 2015; **8**: ra75 [PMID: 26221053 DOI: 10.1126/scisignal.aaa8441]

45 **Jung HS**, Seo YR, Yang YM, Koo JH, An J, Lee SJ, Kim KM, Kim SG. Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation. *Cell Signal* 2014; **26**: 1456-1465 [PMID: 24631529 DOI: 10.1016/j.cellsig.2014.02.022]

46 **Svoronos AA**, Engelman DM, Slack FJ. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. *Cancer Res* 2016; **76**: 3666-3670 [PMID: 27325641 DOI: 10.1158/0008-5472.CAN-16-0359]

47 **Mo Y**, Lu Y, Wang P, Huang S, He L, Li D, Li F, Huang J, Lin X, Li X, Che S, Chen Q. Long non-coding RNA XIST promotes cell growth by regulating miR-139-5p/PDK1/AKT axis in hepatocellular carcinoma. *Tumour Biol* 2017; **39**: 1010428317690999 [PMID: 28231734 DOI: 10.1177/1010428317690999]

48 **Guerrieri F**. Long non-coding RNAs era in liver cancer. *World J Hepatol* 2015; **7**: 1971-1973 [PMID: 26261686 DOI: 10.4254/wjh.v7.i16.1971]

49 **Guo S**, Chen W, Luo Y, Ren F, Zhong T, Rong M, Dang Y, Feng Z, Chen G. Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. *Int J Clin Exp Pathol* 2015; **8**: 5395-5402 [PMID: 26191242]

50 **Eißmann M**, Gutschner T, Hämmerle M, Günther S, Caudron-Herger M, Groß M, Schirmacher P, Rippe K, Braun T, Zörnig M, Diederichs S. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. *RNA Biol* 2012; **9**: 1076-1087 [PMID: 22858678 DOI: 10.4161/rna.21089]

51 **Kong Q**, Zhang S, Liang C, Zhang Y, Kong Q, Chen S, Qin J, Jin Y. LncRNA XIST functions as a molecular sponge of miR-194-5p to regulate MAPK1 expression in hepatocellular carcinoma cell. *J Cell Biochem* 2018; **119**: 4458-4468 [PMID: 29227532 DOI: 10.1002/jcb.26540]

52 **Ohaegbulam KC**, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. *Trends Mol Med* 2015; **21**: 24-33 [PMID: 25440090 DOI: 10.1016/j.molmed.2014.10.009]

53 **Liu D**, Zhu Y, Pang J, Weng X, Feng X, Guo Y. Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195. *J Cell Biochem* 2018; **119**: 1368-1380 [PMID: 28722813 DOI: 10.1002/jcb.26297]

54 **Zhu K**, Wang W. Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1. *Tumour Biol* 2016; **37**: 4373-4382 [PMID: 26499783 DOI: 10.1007/s13277-015-4187-3]

55 **Coombs MR**, Harrison ME, Hoskin DW. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. *Cancer Lett* 2016; **380**: 424-433 [PMID: 27378243 DOI: 10.1016/j.canlet.2016.06.023]

56 **Abtin M**, Alivand MR, Khaniani MS, Bastami M, Zaeifizadeh M, Derakhshan SM. Simultaneous downregulation of miR-21 and miR-155 through oleuropein for breast cancer prevention and therapy. *J Cell Biochem* 2018; **119**: 7151-7165 [PMID: 29905007 DOI: 10.1002/jcb.26754]

**Footnotes**

**Institutional review board statement:** The use of human tissue samples and clinical data was approved by the ethics committee of the German University in Cairo, all patients provided signed informed consent, and the research was carried out in accordance with the Helsinki Declaration.

**Conflict-of-interest statement:** The authors have no conflicts of interests.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** June 30, 2020

**First decision:** September 14, 2020

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Egypt

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Aoki T, Hu B **S-Editor:** Zhang L **L-Editor:** Webster JR **P-Editor:**


**Figure Legends**

****


**Figure 1 Relative expression level of programmed death ligand 1 in liver tissues.** Endogenous programmed death ligand 1 expression profile was analyzed in hepatocellular carcinoma patients, cirrhotic and healthy controls using quantified real-time polymerase chain reaction and normalized to B2M as an internal control (housekeeping gene). Screening of programmed death ligand 1 showed that it was enhanced in cirrhotic biopsies (a*P* < 0.05) and hepatocellular carcinoma biopsies (b*P*< 0.01) compared to healthy controls. HCC: Hepatocellular carcinoma.

****


**Figure 2 Expression profile of lnc-ribonucleic acid X-inactive specific transcript and MALAT-1 in hepatocellular carcinoma tissues.** Endogenous X-inactive specific transcript and MALAT-1 lnc**-**ribonucleic acids expression profile was analyzed in hepatocellular carcinoma (HCC) patients and healthy controls using quantified real-time polymerase chain reaction and normalized to B2M as an endogenous control. A: X-inactive specific transcript lnc-ribonucleic acid showed a significant upregulation in HCC biopsies (*P* = 0.048); and B: MALAT-1 was significantly down regulated in HCC biopsies (*P* = 0.043); however, it showed elevated expression in cirrhotic biopsies (*P* = 0.0136). a*P*< 0.05. HCC: Hepatocellular carcinoma.

****


**Figure 3 Transfection efficiency in Huh-7 cells with miR194-5p and miR-155-5p oligonucleotides.** Using quantified real-time-polymerase chain reaction, the transfection efficiency was determined in both mimicked and mock cells 48 h post-transfection for each of the respective mi-ribonucleic acids. MiR-194-5p and miR-155-5p were normalized to RNU6B as an endogenous control. A: Mimicking of miR-194-5p; and B: miR-155-5p resulted in an increase in each of the respective miRNAs, (*P* = 0.0026) and (*P* < 0.0001), respectively. The expression levels were compared with the unpaired Student’s *t*-test. b*P* < 0.01 and c*P*< 0.001.

****


**Figure 4 Impact of miR-194-5p and miR-155-5p on programmed death ligand 1 transcript expression in Huh-7 cells.** Following ectopic expression manipulation of (A) miR-194-5p and (B) miR-155-5p in Huh-7 cells, programmed death ligand 1 (PD-L1) transcript expression was assessed using quantified real-time polymerase chain reaction and normalized to B2M as an endogenous control. Mimicking of each of the respective miRNAs resulted in significant upregulation of PD-L1 compared to mock untransfected cells (*P* = 0.0219) and (*P* = 0.0209), respectively. On the contrary, PD-L1 transcript expression was significantly downregulated by antagonizing each of the miRNAs in comparison with the mock untransfected cells. a*P*< 0.05.

****


**Figure 5 Impact of miR-155-5p and miR-194-5p on lnc-ribonucleic acids X-inactive specific transcript and MALAT-1 expression in Huh-7 cells.** Expression levels of lnc-ribonucleic acids X-inactive specific transcript and MALAT-1 were assessed following transfection of miR-194-5p and miR-155-5p oligomirs using quantified real-time polymerase chain reaction and normalized to the endogenous B2M as a housekeeping gene. A: Ectopic expression of both miR-155 and mir-194 resulted in significant upregulation of X-inactive specific transcript expression, (*P* = 0.0477) and (*P* = 0.0026) respectively, compared to mock cells; and B: However, a paradoxical effect of mimicking miR-194-5p and miR-155-5p on MALAT-1 expression profile was observed, as miR-194-5p stimulated the upregulation of MALAT-1 expression (*P* = 0.0135), whereas mimicking miR-155-5p induced downregulation of MALAT-1 expression in comparison to mock cells (*P* = 0.0053).a*P* < 0.05 and b*P*< 0.01.

****


**Figure 6 Impact of knockdown of long non-coding ribonucleic acids MALAT-1, X-inactive specific transcript and the negative regulator of X-inactive specific transcript on programmed death ligand 1 expression in Huh-7 cells.** Using quantified real-time polymerase chain reaction, the expression profile of programmed death ligand 1 (PD-L1) transcript was determined following transfection of Huh-7 cells with each of the siRNAs for lncRNAs MALAT-1, X-inactive specific transcript and the negative regulator of X-inactive specific transcript. Values were normalized to an endogenous housekeeping gene B2M. PD-L1 expression was induced following knockdown of MALAT-1 (*P* = 0.0010) compared to mock cells. On the contrary, following down regulation of the negative regulator of X-inactive specific transcript, PD-L1 transcript expression was significantly induced (*P* = 0.0358) compared to mock cells. PD-L1 expression level was totally unaffected by knocking down MALAT-1 in comparison with mock cells. TSIX: The negative regulator of X-inactive specific transcript.

****

**Figure 7 Net impact of ectopic miR-194-5p and miR-155-5p expression on programmed death ligand 1 expression in the presence of siRNA of lnc-ribonucleic acids X-inactive specific transcript, the negative regulator of X-inactive specific transcript and MALAT-1.** The impact of both tumour suppressor miR-194-5p and oncogenic miR-155-5p on programmed death ligand 1 (PD-L1) expression in Huh7 cells in the presence of long non-coding ribonucleic acid X-inactive specific transcript (XIST), the negative regulator of X-inactive specific transcript and MALAT-1 siRNA was similar. Both miRNAs induced upregulation of PD-L1 expression when each was accompanied by MALAT-1 siRNA, while knockdown of the long non-coding ribonucleic acid the negative regulator of X-inactive specific transcript, *i.e.* upregulation of XIST expression, in the presence of miR-155-5p and miR-194-5p mimics down regulated PD-L1 expression. Ectopic expression of each of the miRNAs with knockdown of XIST had no net impact on PD-L1 expression. a*P* < 0.05 and b*P*< 0.01. TSIX: The negative regulator of X-inactive specific transcript.

****

**Figure 8 Impact of oleuropein on the expression profile of the study key players.** The expression pattern of programmed death ligand 1 (PD-L1), micro ribonucleic acids 194-5p and 155-5p as well as long non-coding ribonucleic acids X-inactive specific transcript (XIST) and MALAT-1 were assessed following oleuropein treatment. Values for micro ribonucleic acids were normalized to RNU6B while that for PD-L1, XIST and MALAT-1 were normalized to B2M. Enhanced expression of miR-194-5p was observed following oleuropein treatment (*P* = 0.0022). However, PD-L1, XIST and miR-155-5p expression pattern were down regulated, (*P* = 0.0011), (*P* = 0.0020) and (*P* = 0.0001), respectively. Oleuropein did not show any significant impact on MALAT-1 expression profile. b*P*< 0.01 and c*P* < 0.001.

****

**Figure 9 Schematic representation of the shared pathway between miR-155-5p and miR-194-5p.** This article highlights the novel shared upstream regulatory signaling pathways for programmed cell-death protein 1/programmed death ligand 1 immune checkpoint between paradoxically acting miR-194-5p and miR-155-5p, through lnc X-inactive specific transcript expression modulation. Mimicking of tumor suppressor miR-194-5p as well as oncomiR-155-5p in the Huh-7 cell line showed the same upregulation pattern of X-inactive specific transcript. X-inactive specific transcript was proposed then to be an intermediate player whose upregulation derived the increase in programmed death ligand 1 transcript abundance.

**Table 1 Clinical assessment of 23 patients with hepatocellular carcinoma**

|  |  |
| --- | --- |
| Parameter | Value |
| Age (yr) | 49 ± 13.5 |
| Aspartate aminotransferase (U/L) | 100.5 ±6 5.8 |
| Alanine aminotransferase (U/L) | 85.6 ± 95.6 |
| Alkaline phosphatase (U/L) | 110.2 ± 60.7 |
| Serum albumin (g/dL) | 4.6 ± 1.5 |
| Serum α fetoprotein (ng/mL) | 155.7 ± 22.3 |

Data are presented as the mean ± SD. Male: female = 2:1. All patients were positive for hepatitis C virus antibody.